Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 20

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 20
---
 appointed
Patrick Horsman, an affiliate of the Services Provider, as the Chief Investment Officer of the Company. Mr. Horsman receives
monthly consulting compensation of $29,167 for serving as the Company’s Chief Investment Officer but is not an executive
officer of the Company. Mr. Horsman is also an affiliate of the Strategic Advisor, which together with its affiliates provides
services to the Company for compensation in excess of $120,000 on an annual basis.

Restructuring Plan

As disclosed in our Current Report on Form 8-K
filed on June 27, 2025, we announced a strategic restructuring and realignment of resources to focus exclusively on our synthetic
DNA manufacturing business, LineaRx. As part of the actions undertaken, we implemented a workforce reduction of approximately 27% of headcount
as of June 27, 2025 and have ceased operations at Applied DNA Clinical Labs (“”), a business that provides
molecular and genetic testing services, effective June 27, 2025.

Our actions were intended to substantially reduce
our operating costs and concentrate resources behind LineaRx to: (i) enhance the capabilities of LineaRx’s LineaDNA™
and LineaIVT™ platforms while scaling commercial adoption; (ii) expand our service offerings; and (iii) pursue strategic
partnerships. As of June 27, 2025, the workforce reduction equated to a projected 23% reduction in annual payroll costs, excluding
payroll expenses incurred as a result of the previously announced retirement of our former Chairman and Chief Executive Officer. The projected
annual payroll savings were expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges
related to the workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. We incurred the majority of workforce
reduction-related costs related to this restructuring by the end of the quarterly period ending September 30, 2025, excluding expenses
associated with the retirement of the Company’s former Chairman and Chief Executive Officer.

As disclosed in our Current Report on Form 8-K
filed on October 6, 2025, our board of directors (the “Board”) authorized, and our officers implemented, a further restructuring
plan pursuant to which we will reduce overall operating expenses to focus resources on our BNB Strategy. The restructuring plan includes
a reduction of our current workforce as of September 30, 2025 by sixteen employees, or